1. Spain Stocks

  2. •

    Health technology

  3. •

    Medical specialties
PRIM, S.A.

PRIM, S.A.

12.70
EUR
0.00
(0.00%)
0.80EPS
14.02P/E
192.20MMarket Cap
Mar 03Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5.12
5.51
5.78
6.58
7
7.76
8.71
8.51
9.79
11.56
12.73
13.7
14.8
9.27
Basic EPS, GAAP
0.57
0.58
0.62
0.78
0.8
0.81
0.65
0.4
1.01
0.49
0.74
0.64
0.98
0.8
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.19
0.2
0.53
0.38
0.46
0.58
0.58
0.44
0.31
0.52
0.37
0.45
0.47
- -
Book Value per Share
4.93
5.41
5.4
5.82
6.12
6.28
6.41
6.45
7.11
7.03
7.4
7.58
8.09
6.87
Tangible Book Value per Share
4.83
5.3
5.3
5.42
5.7
5.79
5.94
6.01
6.56
5.92
6
6.16
6.73
6.4
Basic Weighted Avg Shares
17
17
17
17
17
17
17
17
17
17
17
17
17
17
Sales/Revenue/Turnover
87
94
99
110
121
134
151
147
169
197
217
233
252
161
Operating Margin (%)
10.96
11.52
12
11.83
12.61
12.62
10.08
9.7
10.18
5.86
7.34
6.14
10.19
12.33
Depreciation Expense
2
2
2
2
2
3
5
6
7
8
10
11
12
6
Net Income, GAAP
10
10
11
13
14
14
11
7
17
8
13
11
17
14
Effective Tax Rate (%)
30.28
30.25
26.77
12.04
23.97
23.79
34.07
25.95
24.44
22.83
25.57
23.83
23.5
26.28
Profit Margin (%)
11.15
10.57
10.79
11.9
11.46
10.5
7.43
4.7
10.34
4.25
5.85
4.68
6.63
8.57
Working Capital
56
57
62
65
71
72
76
86
90
83
82
85
94
90
LT Debt
3
1
- -
- -
- -
- -
3
13
11
12
9
8
7
12
Total Equity
84
93
92
101
106
109
111
112
121
120
126
129
138
118
Return on Invested Capital (%)
7.71
8.68
8.61
11.47
10.91
11.63
8.7
8.16
9.58
5.09
8.07
7.88
11.28
10.27
Return on Capital (%)
11.29
10.87
11.3
13.34
13.21
13.04
9.97
5.58
12.85
6.1
9.05
7.66
11.33
10.17
Return on Common Equity (%)
12.05
11.29
11.58
13.57
13.43
13.14
10.2
6.21
14.94
6.96
10.32
8.57
12.52
11.9

Capital Structure

EUR

•

in mil. unless spec.
Dec'20
Mar'21
Jun'21
ST Debt
7
7
8
LT Borrowings
11
12
12
LT Finance Leases
2
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
17
17
17
Market Capitalization
168
180
192

Working Capital

EUR

•

in mil. unless spec.
Dec'20
Mar'21
Jun'21
Total Current Assets
124
128
131
Cash, Cash Equivalents & STI
35
38
38
Accounts Receivable, Net
38
37
40
Inventories
46
51
51
Total Current Liabilities
38
36
41
Payables & Accruals
- -
- -
- -
ST Debt
7
7
8
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.14%
4.32%
6.76%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
16.12%
38%
52.77%
Sales/Revenue/Turnover
9.88%
11.38%
8.01%
Total Cash Common Dividend
2.84%
6.38%
5%

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
233
2025
- -
- -
252
2026
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.64
2025
- -
- -
0.98
2026
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.45
2025
- -
- -
0.47
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Fernando Juan Oliveros Arreaga
Full Time Employees
984
Sector
Health technology
Industry
Medical specialties
Address
Polígono Industrial número 1 Mostoles MA Spain 28938
IPO Date
Jan 21, 1997
Website
prim.es
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Prim, S.A. (PRM.MC) operates as a leading provider of healthcare technology, mobility aids, and hospital supplies in Spain, offering a comprehensive range of orthopedic and medical products including collars, clavicle supports, arm slings, hand and finger orthoses, shoulder, elbow, wrist, calf, thigh, hip, and knee braces; back supports, bands, corsets, hyperextension braces, thoracic protectors, and implantable orthopedic devices under brands such as airtex PRO, bruxi calm, fisionprim; as well as physiotherapy equipment, rehabilitation materials, thalassotherapy and thermal therapy products, geriatrics aids, daily living assistance devices, and custom manufacturing services through its medical technologies, mobility, and healthcare segments. Founded over 150 years ago and headquartered in Móstoles, Spain, the company maintains operational headquarters, eight delegations, five factories, 32 orthopedic facilities, and three custom workshops across Spain, with international expansion into Europe including Italy, Portugal, and Asia markets such as Japan and China. PRIM employs over 942 people and reported 2024 turnover of 233 million euros with EBITDA of 28.2 million euros as of December 31, 2024, focusing on healthcare professionals, hospitals, rehabilitation centers, and end-users seeking innovative solutions for mobility, independence, and quality-of-life improvements. In recent developments, PRIM finalized acquisitions of Italian physiotherapy firm Easytech and Spanish orthotics company Teyder in 2022 to bolster technological capabilities in orthotics, physio-aesthetics, and mobility products, alongside earlier purchases of Laboratorios Herbitas, Aura Robotics, and Portuguese firm Farma Mais to accelerate its 2025 Strategic Plan through organic growth and synergies; the company also achieved a 51% net profit increase to 12.6 million euros in 2023 with 9.8% sales growth, earned the efr Family-Responsible Company seal in 2024 for work-life balance, and advanced ESG goals by redesigning packaging in 2024 to reduce environmental impact.